-
91.
公开(公告)号:EP3882264A1
公开(公告)日:2021-09-22
申请号:EP20164619.7
申请日:2020-03-20
申请人: Universität zu Köln
摘要: The present invention relates to a column comprising a vascular endothelial growth factor (VEGF) dimer molecule, a method for preparing such a column, a VEGF dimer molecule, an expression vector and a recombinant host cell encoding for a VEGF dimer, as well as uses and methods related thereto.
-
公开(公告)号:EP3878447A1
公开(公告)日:2021-09-15
申请号:EP20162433.5
申请日:2020-03-11
申请人: InterAx Biotech AG
发明人: Waldhoer, Maria , Zenone, Luca , Wilhelm, Florian , Zimmermann, Mirjam , Ostermaier, Martin Konrad , Scharf, Magdalena Martina , Kolb, Peter
摘要: The present invention relates to a β-adrenergic receptor antagonist and provides compositions and pharmaceutical compositions for the treatment, amelioration and / or prevention of disease.
-
公开(公告)号:EP3685848B1
公开(公告)日:2021-09-15
申请号:EP20150385.1
申请日:2014-11-21
-
公开(公告)号:EP2937348B1
公开(公告)日:2021-09-08
申请号:EP13864994.2
申请日:2013-12-23
发明人: JIANG, Chen , WANG, Aichen , ZHANG, Dedong
-
公开(公告)号:EP3870590A1
公开(公告)日:2021-09-01
申请号:EP19790026.9
申请日:2019-10-25
申请人: Quantum Genomics , Institut National de la Santé et de la Recherche Médicale , Centre national de la recherche scientifique , College de France
IPC分类号: C07F9/30 , A61K31/662 , A61P9/10 , A61P9/12
-
公开(公告)号:EP3865472A1
公开(公告)日:2021-08-18
申请号:EP20212296.6
申请日:2016-06-13
发明人: KINSELLA, B. Therese , REID, Helen
IPC分类号: C07C311/58 , A61K31/64 , A61P3/10 , A61P7/02 , A61P9/00 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/08 , A61P13/12 , A61P29/00 , A61P35/00 , A61P43/00
摘要: The invention relates to novel chemical entities that act as thromboxane (TX) A 2 receptor, or T prostanoid receptor (TP), antagonists and to their use in the treatment of human diseases in which thromboxane (TX) A and of all other agents that act as incidental ligands of TP, including the endoperoxide prostaglandin (PG)G 2 /PGH 2 , 20-hydroxyeicosatetraenoic acid (20-HETE) and the free -radical derived isoprostanes (e.g., 8-iso-prostaglandin (PG)F 2α ), play a role. Compounds of the invention preferably include a benzenesulfonyl urea in which the benzene is substituted by a substituted biphenylyloxy group (e.g., at the 2 position) and by a nitrile group (e.g., at the 5 position), which compounds show promising results as TP-isoform selective TP antagonists.
-
公开(公告)号:EP3381904B1
公开(公告)日:2021-07-28
申请号:EP16857539.7
申请日:2016-10-21
发明人: SAKAKIBARA, Ryo , USHIROGOCHI, Hideki , SASAKI, Wataru , ONDA, Yuichi , YAMAGUCHI, Minami , AKAHOSHI, Fumihiko
IPC分类号: C07D213/74 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61P9/12 , C07D237/20 , A61K31/5355 , C07D417/12
-
公开(公告)号:EP3220940B1
公开(公告)日:2021-07-21
申请号:EP15860292.0
申请日:2015-11-19
-
公开(公告)号:EP2714735B1
公开(公告)日:2021-07-21
申请号:EP12792320.9
申请日:2012-06-01
-
公开(公告)号:EP3835291A1
公开(公告)日:2021-06-16
申请号:EP20208944.7
申请日:2016-06-14
申请人: Corsair Pharma, Inc.
IPC分类号: C07D309/08 , C07C69/28 , C07C69/63 , C07C69/708 , C07C69/712 , C07C69/74 , C07D305/08 , C07D307/30 , A61K31/335 , A61K31/222 , A61P9/12
摘要: The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.
-
-
-
-
-
-
-
-
-